AstraZeneca stock rises after positive Enhertu Phase 3 lung cancer results.
Enhertu improves progression-free survival against current first-line care.
DESTINY-Lung04 supports Enhertu’s move into earlier lung cancer treatment use.
The Phase 3 trial enrolled 454 patients across Asia, Europe and North America.
AstraZeneca plans to share trial data with regulators and medical meetings.
AstraZeneca (AZN) shares rebounded in pre-market trading after the company reported positive results from its DESTINY-Lung04 Phase 3 lung cancer trial. AZN stock rose 0.52% to $157.27 after closing 0.50% lower at $156.45. The results strengthened AstraZeneca’s oncology outlook as Enhertu showed a clear benefit against the current first-line treatment standard.
AstraZeneca reported that Enhertu produced a statistically significant improvement in progression-free survival during the DESTINY-Lung04 study. The trial compared Enhertu with platinum-pemetrexed chemotherapy combined with pembrolizumab in patients with advanced HER2-mutant lung cancer. Therefore, the results support Enhertu’s potential expansion into an earlier treatment setting for eligible patients.
The study focused on patients with unresectable, locally advanced, or metastatic non-squamous non-small cell lung cancer. All participants had tumors carrying HER2 exon 19 or exon 20 mutations. Meanwhile, researchers found no new safety concerns beyond the treatment’s established safety profile during the Phase 3 study.
AstraZeneca and Daiichi Sankyo will continue the study to assess overall survival and other secondary measures. Those measures include response rates, response duration, investigator-assessed progression-free survival, pharmacokinetics, and safety. The companies also plan to present detailed trial findings at an upcoming medical meeting.
Enhertu already holds approvals for previously treated metastatic NSCLC involving activating HER2 mutations in more than 80 countries. DESTINY-Lung04 evaluated the therapy as a first-line option before patients received other systemic treatments. The results could therefore expand Enhertu’s role within AstraZeneca’s growing lung cancer portfolio.
The global first-line standard currently combines immunotherapy with platinum-based chemotherapy for many patients with HER2-mutant NSCLC. Some patients fail to respond adequately or experience disease progression after receiving existing treatment. Consequently, targeted therapies could provide another treatment path for patients with this specific tumor mutation.
HER2 mutations occur in roughly 2% to 4% of patients with non-squamous NSCLC. The mutations appear more frequently among younger patients, women, and people without a smoking history. They have also been associated with aggressive disease characteristics and a greater incidence of brain metastases.
DESTINY-Lung04 enrolled 454 patients across clinical sites in Asia, Europe, and North America. Researchers randomly assigned participants to Enhertu or the existing chemotherapy and immunotherapy combination. They also considered smoking history and brain metastasis status when organizing treatment groups.
Enhertu combines a HER2-targeting antibody with a topoisomerase inhibitor payload using Daiichi Sankyo’s proprietary DXd technology. Daiichi Sankyo discovered the treatment and jointly develops and commercializes it with AstraZeneca. The drug already holds approvals across several breast, lung, gastric, and other HER2-driven cancer settings.
The latest results add another Phase 3 success to AstraZeneca’s broader antibody drug conjugate development program. Regulators will receive the DESTINY-Lung04 findings as AstraZeneca and Daiichi Sankyo pursue potential expanded approvals. Meanwhile, AZN’s pre-market rebound reflected a positive initial market response to the clinical update.
The post AstraZeneca PLC (AZN) Stock: Rebounds as Enhertu Lung Cancer Trial Boosts Shares appeared first on CoinCentral.
